Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
Ann Transl Med
.
2023 Jun 30;11(9):326.
doi: 10.21037/atm-23-1215.
Epub 2023 Apr 4.
Authors
Takuya Maeda
1
,
Teruki Yanagi
1
,
Hideyuki Ujiie
1
Affiliation
1
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan.
PMID:
37405002
PMCID:
PMC10316103
DOI:
10.21037/atm-23-1215
No abstract available
Keywords:
Commentary; clinical trial; melanoma.
Publication types
Editorial
Comment